LBF20207PG31: Difference between revisions
No edit summary |
No edit summary |
||
| (16 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1719 | |LipidBank=XPR1719 | ||
|LipidMaps=LMFA03010036 | |LipidMaps=LMFA03010036 | ||
|SysName=9alpha,11beta,15S- | |SysName=(9alpha,11beta,15S) -Trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&11beta-Prostaglandin | |Common Name=&&11beta- Prostaglandin F_2 alpha&&(9alpha,11beta,15S) -Trihydroxy-prosta- (5Z,13E) -dien-1-oic acid | ||
|Source=11 beta -PGF2 alpha is the primary plasma metabolite of PGD2 in vivo.[[Reference:Liston_TE:Roberts_LJ:2nd:,Proc. Natl. Acad. Sci. U. S. A.,1985,82,6030|{{RelationTable/GetFirstAuthor|Reference:Liston_TE:Roberts_LJ:2nd:,Proc. Natl. Acad. Sci. U. S. A.,1985,82,6030}}]] | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 08:32, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1719 |
| LipidMaps | LMFA03010036 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG31 |
| 11β- Prostaglandin F2α | |
|---|---|
| |
| Structural Information | |
| (9α,11β,15S) -Trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C20H34O5 |
| Exact Mass | 354.240624198 |
| Average Mass | 354.48096000000004 |
| SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@H](C[C@@H]1O)O)CC |
| Physicochemical Information | |
| 11 beta -PGF2 alpha is the primary plasma metabolite of PGD2 in vivo. Liston_TE et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
